Medical diagnostic imaging developer Feedback says that there is strong interest in its TexRAD system and a number of potential partners.
Interim revenues dipped from £225,000 to £203,000 but there were a number of TexRAD research systems installed at the end of the period and, with further orders since then, TexRAD-based revenues will be much higher in the second half.
A deal has been singed with Alliance Medical, which intends to integrate TexRAD into its PET-CT lung cancer imaging service. Further deals are planned and the model is pay-per-use.
There was £63,000 in the bank at the end of November 2016. In the previous six months there was a £43,000 cash outflow. R&D costs have been held down via a collaboration with a Polish software development service. The plan is to agree formal licences for software developed where the two organisations share revenues.
The share price has slipped back to 1.88p, but this is still well above last September’s low.
© 2021 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.